A Phase 1/2 interventional study of Hypoestoxide in Parkinson Disease, sponsored by University of Ibadan. Completed at 1 site in Nigeria. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by University of Ibadan · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Parkinson's disease (PD) is a progressive neurological disease characterized by resting tremors, limb stiffness, impaired balance, and slow movement. There is no known cure for PD although levo-3,4 dihydroxyphenylalanine (L-DOPA) and dopamine agonists are effective for improving PD symptoms in the early years following diagnosis. Hypoestes rosea is an evergreen shrub which has anti-inflammatory, anticancer and antimalarial properties. Recent studies showed that the active pharmaceutical ingredient (API) of Hypoestes rosea, Hypoestoxide, was effective in modifying disease progression in a transgenic mouse model of PD.
The aim of this study is to determine the efficacy of Hypoestoxide, as contained in Hypoestes rosea dry leaf powder, in improving motor symptoms in consenting PD patients. The study design is a double-blind, placebo-controlled cross-over trial involving 30 patients with mild to moderate disease (Stages 1-3 of Hoehn and Yahr scale over an 8-week period. The symptoms of the participants will be monitored using mobile phones with an established quantitative assessment tool, mPower2.0, which was previously developed for monitoring symptoms and disease progression in PD patients. In addition, the motor examination component of the International Movement Disorders Society scale will be administered and correlated with the finding on the mobile phone. The outcome measure is an improvement in the motor variables of the study participants with a 10% change from baseline over the 8 weeks of using Hypoestes.
Justification Age-associated disorders are increasing in many low- and middle-income countries due to population ageing and changing lifestyles. PD is a devastating condition which, in the advanced stages, is associated with immobility and uncontrollable tremors. Life then becomes miserable for the sufferers. Unfortunately, there is no cure for the disease except control of symptoms with medications. Any treatment combination that leads to better symptom control will go a long way in improving the quality of life for PD patients. This proof-of-concept study (POC), if successful will give a new lease on life to PD patients. Hence it is considered worthwhile to treat PD patients with a new compound that is contained in a local plant that is readily available and holds promise for efficacy based on its mode of action specifically in reducing the formation of alpha synuclein which underlies the neuronal death in PD.
OBJECTIVES OF THE STUDY
The aim of this study is to determine the efficacy of Hypoestoxide, as contained in Hypoestes rosea dry leaf powder (PECKO-D), in improving motor symptoms in consenting PD patients over an 8-week period.
Specific Objectives:
Methodology Study site: University College Hospital, Ibadan Study design: Single-center, randomized, double-blind, placebo-controlled trial Study Type: Interventional (Clinical Trial) Allocation: Randomized Masking: Double Primary Purpose: Treatment Study participants: Patients with mild to moderate Parkinson's disease symptoms.
Eligibility Criteria Ages eligible for study: 30 years and older (Adult, older adult) Sexes Eligible for Study: All Accepts healthy volunteers: No Sample size: Being a proof-of-concept study, 19 PD patients will participate in this phase of the study
Inclusion criteria:
Exclusion:
Study Procedure:
In this study, participants with mild to moderate PD, whether treated or untreated, will be randomized into one of two study arms following an initial baseline assessment to determine motor activity status of each participant as follows:
Baseline Determination: Measurement of motor activities of all participants will be determined for 3 weeks while on regular PD medication(s). The International Movement Disorders Society Scale - Motor Examination (10 selected items on Slowness, Posture, Tremor, Rigidity and Gait) will be utilized for the quantitation of the motor activities.
Drug arm: 15 patients will receive 4 capsules each containing 350 mg orally twice a day of PECKO-D Forte for 8 weeks as add-on therapy to patients' regular PD medication(s).
Placebo arm: 15 participants will receive 4 capsules orally twice a day of United States Pharmacopeia (USP)-grade starch for 8 weeks as add-on to regular PD medication(s).
Wash-Out: Wash-out will be for a duration of 4 weeks in which patients assigned to both arms will take no capsules.
The Switch over: Following the wash-out period, the PECKO-D Forte group will receive 4 capsules of USP-grade starch powder taken orally twice a day for 8 weeks. The placebo group will receive 4 capsules of PECKO-D forte taken orally twice a day for 8 weeks.
Symptoms of the participants will be monitored using traditional clinical evaluation and daily using ActiGraph as an established quantitative assessment tool Once enrolled and given the ActiGraph kit, the participants will be asked to perform four (4) separate study tasks daily during the baseline determination period and throughout the treatment period: gait, tremor, tapping and balance. The International Movement Disorders Society Scale (MDS) - Motor Examination (10 selected items on Slowness, Posture, Tremor, Rigidity and Gait) will be utilized for the quantitation of the motor activities. Data collected using the ActiGraph will be computer-analyzed and the MDS - Motor items will then be analyzed for significant changes in symptom severity relative to baseline status.
Measurements:
These include compliance, gait and balance measures before, during, and after treatment with PECKO-D. Participants will remain on their standard of care PD medications throughout the POC study and possible adverse side effects of the PEKO-D will be monitored.
The following variables will be documented for each of these key measures:
i) Compliance: hours of device worn per day hours of device wear compliance per week hours of device worn per treatment period hours of device worn over the course of the study
ii) Gait measures:
start time of walking period in milliseconds end time of walking period in milliseconds Duration of walking period in seconds Distance walked per walking period in meters Average gait speed per walking period in meters Number of steps per walking period Average stride period per walking period in seconds Freeze index per walking period
iii) Balance measures per detected walking period:
OUTCOME MEASURE: 10% Mean change in motor assessment parameters using the International Movement Disorders Society Scale - selected motor examination items while on the Hypoestes. This equates to 1- to 2-point improvement in motor performance over a 2-month period on Hypoestes in the absence of side effects which will be monitored using pharmacovigilance tools.
Total duration of study: 5 months (2 months on active drugs, 2 months on placebo with one month wash-out period in-between)
The protocol for the study:
PROOF OF CONCEPT STUDY: to investigate the effect of PECKO-D Forte (100% Hypoestes rosea powder) in Parkinson's Disease using ActiGraph GT9X wearable as a quantitative assessment tool
Study Protocol
Serial Number: Hospital Number:
Age (in years) Date of Birth (if known):
CLINICAL DETAILS:
Current medications and dosages:
I) L-Dopa + carbidopa ii) Anticholinesterase iii) DOPA-agonists (specify) iv) Others (specify)
Any major disability experienced - Yes No IF yes, check whichever is applicable: Cognitive ______ On and off phenomenon_____ Neuropathic pain_________ Dyskinesia____________ others______________
WILLINGNESS TO PARTICIPATE IN STUDY: Yes No
PECKO-D Study
Objective assessment of motor and non-motor- features in PD patients
The MDS-sponsored Revision of the Unified Parkinson's Disease Rating Scale
0: Normal: No problems.
0: Normal: No problems.
0: Normal: No rigidity.
0: Normal: No problems.
0: Normal: No problems.
0: Normal: No problems. Able to arise quickly without hesitation.
0: Normal: No problems.
0: Normal: No problems. Recovers with one or two steps.
As part of this rating, the patient should sit quietly in a chair with the hands placed on the arms of the chair (not in the lap) and the feet comfortably supported on the floor for 10 seconds with no other directives. Rest tremor is assessed separately for all four limbs and also for the lip/jaw. Rate only the maximum amplitude that is seen at any time as the final rating. Extremity ratings
0: Normal: No tremor.
0: Normal: No tremor.
Severe: Tremor at rest is present > 75% of the entire examination period.
Total Score: (out of 40)
Additional measures include:
Compliance, Gait and Balancing before, during, and after treatment with PECKO-D. Participants will remain on their standard of care PD medications throughout the POC study and possible adverse side effects of the PECKO-D will be monitored.
The following variables will be documented for each of these key measures:
i) Compliance: hours of device worn per day hours of device wear compliance per week hours of device worn per treatment period hours of device worn over the course of the study
ii) Gait measures:
start time of walking period in milliseconds end time of walking period in milliseconds Duration of walking period in seconds Distance walked per walking period in meters Average gait speed per walking period in meters Number of steps per walking period Average stride period per walking period in seconds Freeze index per walking period
iii) Balance measures per detected walking period:
Any abnormality on neurological examination?:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Blood Pressure:
Pulse:
Weight:
Randomization:: A. Active medication: B. Placebo
Mobile Phone serial number: __________________
Follow up data:
I) First review at 8 weeks:
Date scheduled and time:
Compliance
Any reported side effects?: ____________________________________________________
Any benefits noted subjectively?__________________________________________________
Other comments: ________________________________________________
Assess motor performance using the MDS Scale- Record the score_______
II) 4-week washout period: (No study medications to be administered)
Any comments________________________________________________
III) Cross-over for 8 weeks with change of study medications (Placebo to active and vice versa)
Date scheduled and time:
Compliance
Any side effects? ____________________________________________________
Any benefits noted? __________________________________________________
Other comments: ________________________________________________
Assess motor performance using MDS scale: Record the score_______
Study completed: Yes No (If No, give reasons) _____________________
Date completed:
Any comments__________________________________________________________
Name and signature of investigator_____________________________________
Date: ----------------------------
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's enrollment of 19 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →University of Ibadan is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Willing and able to give .
Exclusion Criteria:
Subjects with advanced, severe disease, including those with dementia, severe osteoarthritis, allergies, stroke, and visual impairment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomly allocated to experimental drug
Drug: Hypoestoxide
Corn-Starch will be administered as placebo agent
Drug: Hypoestoxide
Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD
Also known as: PECKO-D forte
motor manifestations
10% Mean change in motor assessment parameters using the International Movement Disorders Society Scale - selected motor examination items while on the Hypoestes. This equates to 1- to 2-point improvement in motor performance over a 2-month period
Time frame: eight weeks
Plan to share: Yes — Sociodemographic and clinical details as well as recordings of the ActiGraph app will be made available
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: Immediately data analysis is completed and for the next 12 months
Access criteria: participants, research collaborators, monitoring and evaluation team
Data sharing details ↗ · www.com.ui.edu.ng
No publications or documents are linked to this record.
Ran from Jan 2022 to primary completion in Sep 2022, 8 months.
Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ibadan